Leave a request
Scientists at the University of Zurich have modified a common respiratory virus called adenovirus to act like a Trojan horse, delivering cancer-curing genes directly to tumor cells. Unlike chemotherapy or radiation therapy, this approach does not harm normal, healthy cells.
Once inside the tumor cells, the delivered genes serve as the basis for therapeutic antibodies, cytokines and other signaling substances that are produced by the cancer cells themselves and act to eliminate tumors from the inside.
Research team leader Andreas Plyukthun explains: "Therapeutic agents, such as therapeutic antibodies or signaling agents, generally remain where they are needed in the body, rather than being spread through the bloodstream, where they can damage healthy organs and tissues."
UZH researchers call their SHREAD technology: from SHielded, REtargetted ADenovirus. It builds on key technologies previously developed by the Plückthun team, including targeting adenoviruses to specific parts of the body to hide them from the immune system.
Large amount of drugs in the tumor, low concentration in other tissues.
Using the SHREAD system, the scientists caused the tumor to produce a clinically approved breast cancer antibody called trastuzumab (Herceptin®) in the mammary gland of a mouse.
They found that after a few days, SHREAD produced more antibodies in the tumor than when the drug was administered directly. Moreover, the concentration of SHREAD in the bloodstream and other tissues where side effects could occur was significantly lower.
By Аvera Allen | Linkedin
#News #Health #Medical #University of Zurich #Tumors #Whealthnews
Leave a request